9.3 What electric hearing sounds like

The 22 electrodes of a typical CI array each excite a population of perhaps a few hundred to a few thousand auditory nerve fibres, with substantial overlap between adjacent electrodes. The 900 pulses-per-second per channel of a typical ACE strategy time-quantises the envelope at about 1 ms resolution. The dynamic range from threshold to comfort is 6–20 dB of electric current, mapped logarithmically from the 80 dB acoustic input. Temporal fine structure is largely discarded; spectral resolution is set by the overlapping current spread; pitch is coded primarily by place (which electrode is active) with limited contribution from the rate of stimulation.

What does this combination of constraints produce perceptually? CI users — those who became deaf as adults and remember normal hearing — provide our best evidence. Their reports converge on a consistent picture: speech becomes intelligible (often within weeks of activation, with continued improvement over a year or two), music sounds “thin” or “tinny” and is harder to enjoy, pitch perception is degraded, and the experience is fundamentally different from normal hearing, not just attenuated.

Pitch in electric hearing

The cochlear implant uses two coding dimensions that loosely correspond to pitch in normal hearing:

• Place pitch. Which electrode is active codes a coarse pitch sensation: apical electrodes sound lower than basal electrodes. The 22 electrodes thus provide a maximum of about 22 discriminable pitch steps across the speech frequency range — compared to the thousands of just-noticeable pitch differences a normal listener perceives.
• Rate pitch. Within a single electrode, the rate of stimulation provides a secondary pitch cue. Stimulation rates between about 100 and 300 pps produce sensations of increasing pitch; above ~300 pps the rate-pitch effect saturates and the listener can no longer distinguish faster rates as higher pitches. This makes rate-pitch useful for low-frequency pitch (where natural fundamentals live) but not for melody perception across a broader range.

CI users with bilateral implants have access to both. The combination is sufficient for speech-prosody coding (which depends on coarse pitch changes, not pitch identification) and for talker-identification (different talkers have different pitch and timbre profiles) but is generally insufficient for melody recognition (most CI users cannot reliably identify familiar songs from melody alone), musical pitch tasks (such as identifying which of two tones is higher), or pitch-based emotion recognition in speech.

Speech intelligibility outcomes

Despite the perceptual limitations, post-lingually deafened adult CI users typically achieve open-set speech understanding within weeks of activation. Median outcomes across thousands of adult CI users:

The variance across patients is enormous — much larger than for hearing aids. Some patients with apparently similar audiograms, similar etiology, similar implants, and similar processing strategies achieve dramatically different outcomes, with no reliable preoperative predictor. Duration of deafness before implantation is the strongest single predictor — patients implanted within 5 years of becoming deaf typically outperform those implanted after 15 years. Etiology matters too (sudden noise/ototoxic vs progressive vs congenital). Cognitive function matters (older patients with declining cognition typically perform worse). Spiral-ganglion-cell survival — the number of auditory nerve cells available for electrical stimulation — matters but cannot be measured directly in living patients.

The lesson: the cochlear implant is a necessary intervention in candidacy-appropriate patients; the outcome depends on many factors the implant itself cannot affect. Counselling pre-implantation appropriately is one of the most important roles of the audiologist in CI care.

The sensitive period in pediatric implantation

Children born with profound bilateral hearing loss — the majority of pediatric CI candidates — receive their implants at progressively younger ages. By 2026 the FDA-approved minimum age in the US is 9 months, but ages as young as 4 months are now routine in major CI centres under research protocols, and the trend is toward earlier implantation.

The evidence for early implantation is overwhelming. Children implanted before 12 months of age develop:

• Spoken language at rates comparable to hearing peers within 24–36 months.
• Speech production with adult-like phonology by age 5–6.
• Reading comprehension at or above grade level.
• Educational placement in mainstream classrooms at rates near typical-hearing children.

Children implanted between 12 and 24 months show smaller but still substantial outcome gains over later-implanted children. Children implanted between 24 and 36 months show further attenuation. Children implanted after age 5 — especially those who had limited exposure to spoken language during the deaf years — typically retain measurable language delays despite the implant, regardless of post-implantation rehabilitation.

The underlying biology is the critical / sensitive period for auditory cortical development. Sharma et al.’s P1 latency studies (see Lesson 6.3 — ASSR and CAEP refresher →) established that children implanted before 3.5 years show normal cortical P1 latency development within 6–8 months of activation, while children implanted after 7 years retain abnormal P1 latencies indefinitely. The cortical machinery that decodes the implant’s electrical output is itself shaped by the input it receives during the early years; deprivation of input prevents the cortex from developing the structures that would later process the input.

This sensitive-period evidence has driven the dramatic shift toward earlier implantation. The 1990s saw the median pediatric implantation age above 3 years; the 2000s saw it drop to 18 months; the 2020s have seen it drop below 12 months for many centres. The newborn hearing screening (Ch 5) is essential infrastructure for early CI candidacy identification — without UNHS, congenital deafness is typically not identified until the child fails to develop expected speech milestones at 18–24 months, by which point much of the sensitive-period window has been lost.

Bilateral and bimodal use

The 1990s assumption — that a single CI was sufficient for restoring useful hearing — has been replaced by routine bilateral implantation (one CI in each ear) when both ears qualify for CI candidacy. Bilateral CIs provide:

• Better speech in noise (3–4 dB additional SNR advantage from binaural summation and head-shadow exploitation).
• Better localisation (limited by ITD encoding in current strategies but functional for left/right discrimination).
• Backup (if one implant fails, the other continues to provide hearing).

Most candidate-eligible patients in 2026 receive bilateral implants, often in a single surgical session.

Bimodal fitting — one CI in the worst ear, one hearing aid in the better ear (which has not yet declined enough to require CI) — is increasingly common. Bimodal users get the CI’s high-frequency electrical hearing combined with the contralateral ear’s residual low-frequency acoustic hearing. Outcomes are often competitive with bilateral CIs at substantially lower cost and surgical risk, and the bimodal configuration preserves any future possibility of stem-cell or gene therapy treatments for the non-implanted ear.

Closing the chapter

That closes Chapter 9. The arc: when the cochlea’s hair cells are gone, the cochlear implant bypasses them by delivering electrical pulses directly to the auditory nerve via an array of 16–22 platinum electrodes. The electrode array has limited spatial selectivity (current spread blurs adjacent channels) and limited dynamic range (6–20 dB electrically vs 80 dB acoustically), but provides enough channels of envelope information to support open-set speech understanding within weeks of activation. The processing strategies (CIS, ACE, FSP) trade temporal continuity for spectral focus; the choice is more often manufacturer-driven than patient-tailored. Outcomes vary widely across users, with duration of deafness and age at implantation (in pediatrics) being the strongest predictors. The sensitive-period evidence has driven CI candidacy toward younger and younger ages, with implantation under 12 months now routine.

The cochlear implant remains the most successful neural prosthesis in clinical medicine. Its limits define the frontier of what is achievable with current technology and motivate the research directions of the coming decade: better electrode arrays (with closer modiolar approach for lower current spread), DNN-based processing strategies (adaptive to specific listening environments), brainstem and midbrain implants for patients without functional auditory nerves, and emerging biological therapies (gene therapy, stem-cell therapy) that may ultimately replace electrical prosthetics for some etiologies.

The book’s final chapter steps to the other major implanted-device category for specific candidacy populations — the bone-conduction device.

Next chapter: Ch 10 — Bone-conduction devices.